The Board of Pharmacy has received notice of the following product withdrawal:

Description	Lot # / Exp Date	NDC	UPC	
RANITID SRP150/ MLA/F10MLP/A40@	C314 3/21; BDFA 4/20; BFA1 6/20; C019 7/20; C0AD 8/20; C10F 12/20; C110 1/21; C1CD 1/21; C2AA 2/21; C2F7 3/21; BD35 3/20	00121472710	30121472710	
RANITID SYRP 15/ MLA/FP/A 16OZ	BE00 6/20; BDFF 6/20; BDFE 5/20; BDF9 4/20; BD36 3/20; BD33 5/20; BD31 4/20; BF77 7/20; BBCC 3/20; BF78 7/20; BD30 3/20; C11D 1/21; C2B6 3/21; C2A9 2/21; C26A 2/21; C269 2/21; C268 2/21; C267 2/21; C1D1 2/21; C1D0 2/21; BF75 6/20; C11E 1/21; C2F1 3/21; C11C 12/20; C11B 12/20; C11A 12/20; C114 1/21; C113 12/20; C0AC 8/20; C07E 12/20; C07D 8/20; C01A 7/20; C1CC 1/21	00121072716	30121072716	

Pai is withdrawing the above items/lots due to the FDA request that this product be withdrawn from the market due to NDMA impurity increase in the product over time.This withdrawal is to the retail level. Affected product started shipping March 27, 2019.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.